Glass House Brands (GLAS) EBT (2020 - 2026)

Glass House Brands (GLAS) posted quarterly EBT of -$13.9 million for Q1 2026, down 11.28% quarter-over-quarter from -$12.5 million in Q4 2025.

Glass House Brands (GLAS) EBT (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported EBT for 7 consecutive years, with -$13.9 million the latest figure, recorded in Q1 2026.

In Q1 2026, EBT changed N/A year-over-year to -$13.9 million; the TTM figure through Mar 2026 stood at -$23.9 million (changed N/A YoY), while the FY2025 annual figure was -$17.0 million, down 251.69% from the prior year.
EBT declined to -$13.9 million in Q1 2026 per GLAS's latest filing, from -$12.5 million in the prior quarter.
Across five years, EBT topped out at $17.8 million in Q3 2022 and bottomed at -$19659.4 billion in Q2 2023.
Historically, EBT has averaged -$2470.7 billion across 5 years, with a median of -$13.9 million in 2026.
On a YoY basis, EBT climbed as much as 100.0% in 2022 and fell as far as 91.7% in 2022.
Glass House Brands' EBT stood at -$21.5 million in 2022, then sank by 78.4% to -$38.4 million in 2023, then jumped by 126.69% to $10.2 million in 2024, then sank by 222.38% to -$12.5 million in 2025, then retreated by 11.28% to -$13.9 million in 2026.
Business Quant data shows GLAS's EBT at -$13.9 million in Q1 2026, -$12.5 million in Q4 2025, and -$11.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	-455.00 Mn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	866.00 Mn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	1.02 Bn
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	372.70 Mn
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	-64.00 Mn
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	162.20 Mn
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	56.00 Mn
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Glass House Brands	835.49 Mn	816.93 Mn	15.77 Mn	-1.51 Mn

Download Data